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Background: At present, there is no standard of treatment using systemic high-dose corticosteroids in cases of
pregnant women with Vogt-Koyanagi-Harada (VKH) disease. Although high-dose systemic corticosteroid treatment
is often used for VKH disease during pregnancy, it also poses a risk to the fetus.
Findings: A 29-year-old woman in the 34th week of pregnancy experienced bilateral metamorphopsia. She had
been receiving 5 mg of prednisolone daily for the past 8 years as treatment for rheumatoid arthritis. In order to
prevent progression of bilateral serous retinal detachment caused by VKH disease, we recommended the use of
high-dose systemic corticosteroids but the patient refused. Thus, we administered only topical ophthalmic
betamethasone for mild anterior uveitis. Surprisingly, however, the bilateral bullous retinal detachment healed in
just 19 days after the onset of symptoms. A healthy baby was born 1 month later, and sunset glow fundus was
subsequently observed without any recurrence of uveitis.
Conclusions: We report a case in which bilateral subretinal fluid caused by VKH disease in a young woman during
late pregnancy resolved without high-dose corticosteroid treatment. Pregnancy may have had a beneficial effect on
uveitis activity caused by VKH disease. To our knowledge, this report describes the shortest healing period for bilateral
bullous retinal detachment in a pregnant woman with VKH disease.
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Introduction
Although reports have described cases of pregnant women
with Vogt-Koyanagi-Harada (VKH) disease [1–10], no
standard of treatment that includes systemic high-dose
corticosteroids has been established. Previously, a 24-year-
old pregnant woman with VKH disease successfully healed
on the 26th day after onset without the use of systemic or
topical corticosteroids [1]. Here, we report a 29-year-old
pregnant woman who received prednisolone 5 mg/day for
rheumatoid arthritis; she exhibited bullous retinal detach-
ment caused by VKH disease, and the subretinal fluid
successfully resolved in just 19 days after the onset of
symptoms. To our knowledge, this report describes the* Correspondence: zako@aichi-med-u.ac.jp
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provided the original work is properly creditedshortest healing period for bilateral bullous retinal detach-
ment in a pregnant woman with VKH disease.
Case report
On 1 November 2013, a 29-year-old Japanese woman in
the 34th week of her first pregnancy began to experience
acute vision loss in both eyes, coupled with the appear-
ance of metamorphopsia. She visited our hospital on the
following day with bilateral blurred vision with meningis-
mus. The patient’s best corrected visual acuity (BCVA)
was 0.5 in her right eye and 0.3 in her left eye. The patient
had mild iridocyclitis in both eyes. Ophthalmoscopic
examination revealed multi-focal serous retinal detach-
ment (Figs. 1 and 2, day 2). The intraocular pressures were
18 mmHg (right eye) and 12 mmHg (left eye). B-scan
ultrasonography was not performed, and choroidal thick-
ness was unclear. The patient refused fluorescein angiog-
raphy. Her blood pressure was 116/60. Based on these
clinical findings and the revised criteria for diagnosis oficle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
Fig. 1 Color fundus photographs, taken starting the day after the
patient’s initial symptoms (bilateral acute vision loss with
metamorphopsia) appeared. Multi-focal serous retinal detachment
was apparent on day 2 and then reached bullous retinal detachment
on day 12. Without high-dose systemic corticosteroid treatment,
subretinal fluid had nearly disappeared by day 19, and sunset glow
fundus was observed on day 152 without any recurrence of uveitis
Fig. 2 Spectral domain optical coherence tomography on days 2,
12, 19, and 152. Progression and resolution of bilateral serous retinal
detachment caused by VKH disease. R right eye, L left eye
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recommended the use of systemic high-dose corticoste-
roids for the treatment of VKH disease. However, the pa-
tient refused treatment because she was worried about
adverse effects to the fetus. We therefore administered
only topical ophthalmic betamethasone. Because she had
rheumatoid arthritis, the patient had been receiving pred-
nisolone 5 mg daily for the past 8 years. The patient had
no history of any other medical disorders, including
hypertension. She was a non-smoker and did not drink
alcohol while pregnant. Her pregnancy had, up to this
point, been uneventful. She underwent all routinelaboratory and ultrasound tests, and the fetus had devel-
oped normally. Blood cortisol levels during pregnancy
were not investigated.
On 12 November 2013, the patient returned, presenting
with progressive vision loss in both eyes that had begun
4 days earlier. The patient’s BCVA was 0.3 in her right eye
and 0.2 in her left eye. Ophthalmic examination revealed
bullous retinal detachment in both eyes (Figs. 1 and 2, day
12). Intraocular pressures were 10 mmHg (right eye) and
11 mmHg (left eye). However, she continued to refuse
treatment. At a subsequent visit on 19 November 2013,
she reported visual improvement in both eyes. Ophthal-
mic examination on that day revealed the disappearance
of subretinal fluid from both eyes (Figs. 1 and 2, day 19).
Her BCVA was 0.8 in her right eye and 0.9 in her left eye.
Intraocular pressures were 19 mmHg (right eye) and
16 mmHg (left eye). On 27 November 2013, she delivered
a healthy female baby (gestational age 37 weeks and 5 days,
2294 g) by spontaneous vaginal delivery. The baby’s birth
weight was low, but not small for her gestational age. A
subsequent examination on 1 April 2014 revealed that the
patient’s BCVA was 1.0 in both eyes, and examination of
her fundus revealed typical sunset glow fundus, without
subretinal fluid (Figs. 1 and 2, day 152). Intraocular
pressures were 14 mmHg (right eye) and 10 mmHg
(left eye). She exhibited alopecia and poliosis. After
reviewing all of the patient’s clinical findings, we diag-
nosed her with complete VKH. On 11 May 2015, our
final meeting with the patient, she did not exhibit any
recurrence of VKH. The patient was still receiving
5 mg prednisolone daily for rheumatoid arthritis. Prior
to and during her pregnancy, the patient’s blood
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exhibited hypertension.
Discussion
High-dose systemic corticosteroid treatment is often
used for VKH disease during pregnancy [2–7, 10], al-
though some reports indicate that it may also pose a risk
to the fetus. In one such report, Ohta et al. described a
case of fetal death in a 28-year-old Japanese woman who
was being treated with intravenous high-dose prednisol-
one for VKH disease [10]. In another report, Steahly de-
tailed the adverse effects of high-dose corticosteroid
treatment for VKH disease during pregnancy in two
cases: one patient suffered a spontaneous abortion, and
the other delivered a premature infant [5]. Doi et al. also
reported that a pregnant VKH patient treated with a
high-dose systemic corticosteroid delivered a low-birth-
weight infant with an epibulbar dermoid, lipodermoids,
and preauricular appendages, although the relationship
among VKH disease, systemic corticosteroids, spontan-
eous abortion, and congenital malformation was not
clear [6]. Østensen and Skomsvoll stated that, adminis-
tered during early pregnancy, corticosteroids are also
considered a risk factor for the development of oral
clefts [12]. In light of these potential complications, they
have proposed that the daily dose should be kept to
≤15 mg during the first trimester. Miyata et al. suggested
that treatment should be chosen according to the sever-
ity of inflammation, the stage of pregnancy, maternal
condition, and fetal condition. In their report, successful
treatment of three cases of VKH disease during preg-
nancy was demonstrated [7]. One patient with mild
inflammation was treated with a topical corticosteroid,
while two additional cases were treated with a high-dose
systemic corticosteroid. No abnormalities were observed
during or after the deliveries.
The use of high-dose corticosteroids during pregnancy
is associated with premature rupture of the membranes,
intrauterine growth restriction, and the precipitation of
maternal complications such as gestational diabetes,
hypertension, osteoporosis, and avascular bone necrosis
[13]. It should be also noted that prednisone, prednisol-
one, and methylprednisolone have minimal placental
transfer and are the drugs of choice during pregnancy.
On the other hand, fluorinated corticosteroids such as
dexamethasone and betamethasone easily cross the
placenta and therefore should not be used unless there
is intent to treat the fetus [13].
Although an early pregnancy flare-up is typical of
VKH disease [8], pregnancy may have a beneficial effect
on uveitis activity caused by VKH disease [9]. Generally,
during early pregnancy, cellular immunity is suppressed
and the production of inflammatory cytokines is low,
while corticosteroid production is high. Because of theseimmunological conditions, the inflammation caused by
VKH disease during the first and second trimesters of
pregnancy may be mild. Consequently, in our case, VKH
disease may not have appeared during the first and sec-
ond trimesters. In addition, the period of time required
for bilateral absorption of the subretinal fluid was
obviously shorter than in normal VKH patients, even
without high-dose corticosteroid treatment. Steahly
showed that some cases of VKH disease improved
clinically during pregnancy after the discontinuation of
corticosteroid treatment; however, symptoms recurred
after their pregnancies ended [5]. These findings suggest
it might be unnecessary to administer more corticoster-
oid to treat persistent serous retinal detachment after
systemic corticosteroid treatment.
The patient had received 5 mg prednisolone daily for
the past 8 years as treatment for rheumatoid arthritis. It
is unclear whether this daily oral administration of 5 mg
prednisolone contributed to the resolution of VKH in
this patient; however, we do not believe 5 mg of oral
prednisolone is enough to resolve the active phase of
VKH as shown in this case. The precise mechanism is
not clear, as we did not investigate this patient’s serum
hormone levels during pregnancy and neither did her
gynecologist or rheumatologist.
In summary, we report a 29-year-old woman in the
34th week of pregnancy taking prednisolone 5 mg per
day, who exhibited bilateral bullous retinal detachment
as a result of VKH disease. Without administration of
high-dose systemic corticosteroids, subretinal fluid
resolved 19 days after the onset of symptoms, and uveitis
did not recur thereafter. No standard of treatment has
been established for pregnant patients with VKH disease.
In the absence of systemic high-dose corticosteroid
treatment, pregnancy may favorably influence and
modulate the course of the disease, as exemplified by
this patient.Consent
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